Dental Care Clinics in Cascade, ID Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Cascade Family Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 839 S Main St, Cascade, ID 83611 Phone: 208-382-8200 |
Cascade Family Dentistry Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 839 Main St, Ste1, Cascade, ID 83611 Phone: 208-382-8200 Fax: 208-382-6202 |
Two Rivers Dental Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 220 S Main St, Cascade, ID 83611 Phone: 208-382-3558 Fax: 208-382-3668 |
Cascade Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 839 S Main Street, Cascade, ID 83611 Phone: 208-382-8200 |
Cornerstone Family & Cosmetic Dentistry Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 220 South Main Street, Cascade, ID 83611 Phone: 208-382-3558 Fax: 208-382-3668 |
News Archive
Johns Hopkins Ophthalmology professor Bob Massof receives Helen Keller prize
Bob Massof, Ph.D., of the Wilmer Eye Institute at Johns Hopkins received the 2015 Helen Keller Prize for Vision Research on May 5...
Health Canada approves ULORIC to lower serum uric acid levels in patients with gout
Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.
Study finds vaccine to lower cholesterol levels could also immunize against heart disease
In people with high cholesterol levels, the fat that is built up in the artery walls narrows the arteries causing a condition called atherosclerosis. A study published on 19th June in the European Heart Journal has found the likelihood of a vaccine that can immunize humans having atherosclerosis, subsequent to successful outcomes in a mouse model study. At present, phase I clinical trial has begun in patients to see the possibility of translating the study findings to humans.
AVIR Green Hills Biotechnology commences deltaFLU Phase II study
AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.
Hippocampal activity may reflect ‘core' schizophrenia traits
Hippocampal function may be a useful biomarker for the response of patients with schizophrenia to medication, research suggests.
› Verified 2 days ago